The FDA will be reviewing legacy medical devices, those whose use was grandfathered in since they were on the market before the medical device law was established in 1976, reports the New York Times. In the '70s, Congress had instructed FDA to eventually look over the legacy devices and determine which ones would need testing if and when a new version were to come out.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.